News
Clinigen: IL-2 Plays Role in Emerging TIL Therapies
Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company acknowledges the presentation of results from the Phase I trial “Durable complete responses
LivaNova Reports First Quarter 2020 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2020.
For the first quarter of 2020, worldwide sales
LivaNova Bi-Flow-Kanüle erhält CE-Zeichen für ECMO-Anwendungen
LivaNova PLC (NASDAQ:LIVN), ein marktführendes Unternehmen für Medizintechnik und Innovationen, gab heute bekannt, dass seine Bi-Flow-Kanüle für extrakorporale Membranoxygenierung (ECMO) die
LivaNova Bi-Flow Cannula Receives CE Mark for ECMO Applications
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its Bi-Flow Extracorporeal Membrane Oxygenation (ECMO) cannula earned CE Mark approval for
GSK Presents New Data from the GARNET Study Demonstrating Potential of Dostarlimab to Treat a Subset of Women with Recurrent or Advanced Endometrial Cancer
GlaxoSmithKline plc (LSE/NYSE:GSK) today announced data from an updated analysis of the GARNET trial, which demonstrated that dostarlimab, an investigational anti-programmed death-1 (PD-1)
LivaNova Permitted to Modify Cardiopulmonary Products' Indications for Use to Include ECMO Therapy Beyond Six Hours to Address COVID-19
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced that several of its cardiopulmonary products are now permitted to be used in the U.S. for
LivaNova to Host Conference Call for First Quarter 2020 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first quarter 2020 results on Wednesday, April 29, 2020 at 1 p.m
LivaNova Autonomic Regulation Therapy for Heart Failure Findings to be Presented at American College of Cardiology and World Congress of Cardiology Virtual Meeting
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced two abstracts focused on implantable neuromodulation technology for patients with heart
Symmetry, das LivaNova VNS Therapy-System für schwer zu behandelnde Depressionen, erhält CE-Prüfzeichen
LivaNova PLC (NASDAQ:LIVN), ein marktführendes medizintechnisches Innovationsunternehmen, gab heute bekannt, dass sein System Vagus Nerve Stimulation Therapy® (VNS Therapy) Symmetry™ die
LivaNova VNS Therapy System, Symmetry, Granted CE Mark for Difficult-to-Treat Depression
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its Vagus Nerve Stimulation Therapy® (VNS Therapy) System, Symmetry™, earned CE Mark approval
LivaNova Enters Research Collaboration with Verily to Gain New Insights into Vagus Nerve Stimulation Impact on Difficult-to-Treat Depression
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced a research collaboration with Verily, an Alphabet company, to capture measures of depression
LivaNova Reports Fourth Quarter and Full-Year 2019 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full-year ended December 31, 2019.
For the fourth quarter of
LivaNova Receives FDA Clearance for 3T Heater-Cooler Device Modification
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for a device
New International Consensus Statement Proposes “Difficult-to-treat Depression” as a More Clinically Useful Definition than “Treatment-Resistant Depression”
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, commends the recent international consensus statement published in the Journal of Affective Disorders for
LivaNova to Host Conference Call for Fourth Quarter and Full-Year 2019 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its fourth quarter and full-year 2019 results on Wednesday, Feb. 26
Eine neu veröffentlichte multizentrische RCT zeigt, dass Smith+Nephew PICO◊ sNPWT kanisterlose Unterdruck-Wundtherapie herkömmlicher tNPWT bei der Reduzierung von Wundfläche, -tiefe und -volumen bei DFU und UCV überlegen ist
Smith+Nephew (LSE:SN, NYSE:SNN), das globale Medizintechnikunternehmen, freut sich, die Veröffentlichung von Ergebnissen aus einer neuen randomisierten kontrollierten klinischen Studie (RCT)
Clinical trial demonstrated superior wound closure rates with PICO◊ compared to traditional NPWT in lower extremity ulcers1
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces the publication of a new randomized controlled trial (RCT) which demonstrated that the use of PICO Single
Clinigen and Orphazyme launch an Early Access Program for arimoclomol in patients with Niemann-Pick disease type C
Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has partnered with Orphazyme A/S (ORPHA.CO, ‘Orphazyme’), a global biopharmaceutical company dedicated to
Amarin: Vorzeitige Bescherung durch die FDA!
Am vergangenen Freitag, dem 13. Dezember, war die Aktie von Amarin (WKN: A0NBNG) in den USA den größten Teil des Tages vom Handel ausgesetzt. Grund hierfür war eine bevorstehende, Kurs bewegende
LivaNova to Present New Data on Vagus Nerve Stimulation Therapy System at the American Epilepsy Society 2019 Annual Meeting
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it will present new registry data from two patient populations benefiting from Vagus Nerve
LivaNova to Restructure its Heart Valve Business Line and End Caisson Transcatheter Mitral Valve Replacement Program
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it is ending its Caisson Transcatheter Mitral Valve Replacement (TMVR) program and will
LivaNova restrukturiert sein Geschäftsgebiet Herzklappen und beendet das Programm zum Austausch von Mitralklappen mit Caisson-Transkathetern
LivaNova PLC (NASDAQ:LIVN), ein marktführendes Unternehmen der Medizintechnik und Innovation, gab heute bekannt, dass es sein Programm Caisson Transcatheter Mitral Valve Replacement (TMVR) beendet
LivaNova to Present at the Berenberg and Piper Jaffray Conferences
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Thad Huston, Chief Financial Officer, will participate in discussions at the Berenberg European Conference
Amarin: 16:0-Kantersieg beim gestrigen FDA-Meeting
Die Aktie des irisch-amerikanischen Biotechunternehmens Amarin (WKN: A0NBNG) ist schon seit einiger Zeit vom Handel ausgesetzt. Grund für diese Handelsaussetzung war das angekündigte Treffen von
Amarin: 16:0-Kantersieg bei FDA-Meeting
Die Aktie des irisch-amerikanischen Biotechunternehmens Amarin (WKN: A0NBNG) ist schon seit einiger Zeit vom Handel ausgesetzt. Grund für diese Handelsaussetzung war das angekündigte Treffen von